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Background: Pelvic nodal metastasis in prostate cancer impacts patient outcome
negatively.
Objective: To explore tumor-infiltrating immune cells as a potential predictive tool
for regional lymph node (LN) metastasis.
Design, setting, and participants: We applied multiplex immunofluorescence and
targeted transcriptomic analysis on 94 radical prostatectomy specimens in patients
with (LN+) or without (LN–) pelvic nodal metastases. Both intraepithelial and
stromal infiltrations of immune cells and differentially expressed genes (mRNA and
protein levels) were correlated with the nodal status.
Outcome measurements and statistical analysis: The identified CD4 effector cell
signature of nodal metastasis was validated in a comparable independent patient
cohort of 184 informative cases. Patient outcome analysis and decision curve
analysis were performed with the CD4 effector cell density–based signature.
Results and limitations: In the discovery cohort, both tumor epithelium and
stroma from patients with nodal metastasis had significantly lower infiltration
of multiple immune cell types, with stromal CD4 effector cells highlighted as the
top candidate marker. Targeted gene expression analysis and confirmatory protein
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independent predictor of LN metastasis (odds ratio [OR] = 0.15, p = 0.004), and
was further validated as a significant predictor of nodal metastasis in the
validation cohort (OR = 0.26, p < 0.001).
Conclusions: Decreased T-cell infiltrates in the primary tumor (particularly CD4
effector cells) are associated with a higher risk of LN metastasis. Future evalua-
tion of CD4-based assays on prostate cancer diagnostic biopsy materials may
improve selection of at-risk patients for the treatment of LN metastasis.
Patient summary: In this report, we found that cancer showing evidence of
cancer metastasis to the lymph nodes tends to have less immune cells present
within the tumor. We conclude that the extent of immune cells present within a
prostate tumor can help doctors determine the most appropriate treatment plan
for individual patients.
© 2021 Published by Elsevier B.V. on behalf of European Association of Urology. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Prostate cancer (PCa) is the second most prevalent cancer in
men worldwide [1]. During PCa progression, regional lymph
nodes (LNs) are common sites for metastases. Even with the
adoption of the Briganti nomogram and similar strategies,
only around 20% of patients undergoing extended pelvic
node dissection will be confirmed to have histological
evidence of nodal metastasis. There is a lack of sensitive and
specific markers for predicting cancer spread to the LNs at
the time of diagnosis.
Tumor-infiltrating immune cells have previously been
identified as prognostic and predictive biomarkers in
several cancers [2–7]. The exact immune cell subpopula-
tion, and its functional polarization and spatial distribution
have been shown to influence cancer aggressiveness,
metastatic potential, and clinical outcome for cancer
patients [4,5,8]. Therefore, the in situ cancer immune cell
composition may have direct clinical implications for
prognosis as well as therapeutic responses.
Multiplex immunofluorescence (mIF) has been instru-
mental in the investigation of the tumor microenvironment.
Fluorescent signals are easily quantifiable due to their linear
and additive nature, allowing for more objective and
reproducible quantitation compared with chromogenic
immunohistochemistry (IHC) [9]. The benefits of multi-
plexing with tyramide signal amplification lie in collecting
maximum information from a single tissue section
[10]. Therefore, cell populations can be classified accurately,
and their spatial associations and frequency of coexpression
among different cell types can be determined [4,11].
The reported relationships between tumor-infiltrating
immune cells in PCa with patient outcomes have varied
widely in the literature. Several studies have associated
different immune cells, such as macrophages, and CD8 and
CD4 T lymphocytes, with PCa patient survival; however,
these results have been inconsistent [12–16]. Therefore, it is
essential to study the baseline immune status of high-risk
disease in order to gain a better understanding of disease
progression and to inform treatment plans. In this study, we
hypothesized that a local immune cell signature can predict
pelvic nodal metastasis. We further investigated forpotential correlation between tumoral immune infiltrates
and common genetic alterations in PCa, such as ERG
translocation and loss of PTEN expression.
We characterized the tumor immune infiltrates within
radical prostatectomy (RP) specimens by mIF, along with
targeted transcriptomic analysis of the tumor microenvi-
ronment. We identified a CD4 effector cell–based tumoral
immune signature of LN+ disease, which was then validated
in a comparable independent patient cohort. Together, we
explored the possibility of exploiting the immune landscape
of intermediate- and high-risk PCa as potential prognostic
markers for nodal metastasis.
2. Patients and methods
2.1. Discovery cohort
Formalin-fixed, paraffin-embedded (FFPE) histological sections from
intermediate- and high-risk PCa patients who underwent RP and
lymphadenectomy with curative intent (50 with and 45 without LN
metastasis) were retrospectively identified between June 04, 2008, and
January 23, 2018, at Queen Elizabeth University Hospital in Glasgow. All
patients found positive for pelvic node following RP and pelvic node
dissection in this period were selected for an analysis. A similar number
of patients with similar clinicopathological factors but negative for pelvic
nodes following surgery were then included as controls.
2.2. Validation cohort
To validate findings from the discovery cohort, we studied a tissue
microarray (TMA) of RP specimens containing primary PCa from
University of Bern. This included 285 patients with primary PCa who
underwent RP. A total of 251 patients had one 0.6 mm core and
34 patients had two 0.6 mm cores from the PCa index lesion. Data from
184 cases were informative with adequate cancer content in the tissue
samples and interpretable images following staining.
2.3. Laboratory investigations
Methodologies for the following are provided in the Supplementary
material:
1 Construction of a TMA
2 Multiplex immunofluorescence staining
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4 Transcriptomic analysis of FFPE tissue using HTG EdgeSeq Precision
Immuno-Oncology Panel (Supplementary Table 1)
5 Manual chromogenic IHC and scoring
6 Second harmonic generation (SHG) image acquisition and analysis for
the determination of collagen quantity and quality
2.4. Statistical methods
Statistical analyses were carried out with Graph Prism 8 and IBM SPSS
statistics 25. R v3.5.2 software was used for creating CD4 effector T-cell
density plots, survival analysis, receiver operator characteristic (ROC)
analysis, and decision curve analysis. Comparisons between groups were
conducted using Mann–Whitney U tests (unpaired, nonparametric, two
tailed), and Fisher’s and chi-square tests where appropriate. Kaplan-
Meier curves were compared using Cox’s proportional hazards regres-
sion model. ROC curve analysis and multivariate logistic regression
models were used to identify predictive factors of LN metastasis. For the
targeted gene expression panel, HTG reveal software was used for
statistical analysis using the DESeq2 test with an adjusted p value of
<0.05 and a log fold change value of >1.5.
3. Results
3.1. Clinicopathological characteristics
Patient clinicopathological characteristics included in the
discovery TMA are presented in Table 1. Besides their age,
patients with and without LN metastasis (LN+, n = 50 and
LN–, n = 44, respectively) have highly comparable clinico-
pathological parameters (including the number of excised
LNs, preoperative prostate-specific antigen [PSA] levels, pT
stage, Gleason score, and presence of perineural invasion).
3.2. Tumoral immune infiltrates are associated with pelvic
nodal disease
We developed two mIF protocols, which allowed for the
simultaneous evaluation of up to six markers in a single
FFPE tissue section (Figs. 1 and 2). Each tissue core was
visually examined, and cores with benign tissue, tissueTable 1 – Clinical and histopathological characteristics of the discovery 
Overall 
N = 94 
Age at diagnosis, median (95% CI) 65 (63–66) 
Number of lymph nodes excised, median (95% CI) 15 (13–17) 
Peak PSA, median (95% CI) 14.8 (12.3–16.7) 
Stage, N (%) 
pT2 34 (36.17) 
pT3-T4 60 (63.83) 
Gleason score, N (%) 
7 65 (69.15) 
>7 (8–9) 29 (30.85) 
PNI, N (%) 
Negative 15 (15.96) 
Positive 79 (84.04) 
Relapse-free survival, median (95% CI) 39 (44.3–33.6) 
CI = confidence interval; LN = lymph node; PNI = perineural invasion; PSA = pro
Mann-Whitney and Fisher’s exact tests were used for statistical calculations.folding, or staining artifacts were excluded. The immune
cell densities were quantified within the epithelial and
stromal compartments separately.
Tumors with LN metastasis generally had less immune
infiltration (Table 2 and Fig. 3), with significant reduced
tumor (both intraepithelial and stromal) infiltration by M1-
like macrophages and CD8 effector T cells. Of particular
interest, stromal CD4 effector T-cell infiltration showed a
large difference between LN– and LN+ tumors: 32.5 versus
91.35 cells/mm2 (p < 0.001; Table 2). There were no
significant differences in M2-like macrophages, B cells,
CD4 regulatory T cells, CD8 regulatory T cells, CD4 PD-1–
positive T cells, and CD8 PD-1–positive T cells between
patients with or without LN involvement.
3.3. Common molecular changes in PCa did not correlate with
immune cell densities
Of the 94 patients in our TMA, 92, 91, and 89 had at least two
out of three evaluable cores for ERG, PTEN, and Ki67 staining
by IHC, respectively (Supplementary Table 2 and Supple-
mentary Fig. 2). Consistent with the reported incidence of
TMPRSS2/ERG translocation [17,18], 43/92 (47%) stained
positive for ERG. However, ERG immunoreactivity did not
correlate with nodal metastasis (p = 0.836). PTEN staining
was detected in 52/91 (57%) patients. Consistent with
previous reports [19,20], with PTEN loss significantly
associated with nodal metastasis (p < 0.001). Overall,
immune cell infiltrates did not correlate with ERG status,
PTEN status, or proliferation index (Ki67 staining; Supple-
mentary Tables 3–5).
3.4. Transcriptomic analysis highlighted the association
between altered tumor extracellular matrix and nodal status
To gain additional insight into the molecular mechanisms
associated with LN+ prostate tumors, we used a targeted
HTG EdgeSeq Immuno-Oncology panel (Supplementary
Table 1) to compare LN+ versus LN– prostate tumors.TMA of patients with (LN+) and without (LN–) lymph node metastasis
Lymph node metastasis
LN–, n = 44 LN+, n = 50 p value
67 (66–70) 62 (59–65) <0.001
17 (14–18) 13.5 (10–17) 0.051
15.5 (11.5–17.7) 14.2 (11–17) 0.831
0.089
20 (45.45) 14 (28)
24 (54.55) 36 (72)
0.109
34 (77.27) 31 (62)
10 (22.73) 19 (38)
0.156
10 (22.73) 5 (10)
34 (77.27) 45 (90)
39 (53.9–41.5) 40 (57.1–39.8) 0.404
state-specific antigen; TMA = tissue microarray.
Fig. 1 – Application of a macrophage and B-cell multiplex immunofluorescence panel in prostate cancer primary tumors. (A) A spectrally unmixed
prostate cancer core stained with the macrophage and B-cell panel (panel 1). Enlarged subsections of the core highlighted in Figure 1A, showing each
markers of the composite image individually after spectral unmixing, together with DAPI nuclear marker (blue pseudocolor) and autofluorescence
signal (black pseudocolor): (B) CD68 (labeled with Opal 520, green pseudocolor), (C) CD163 (labeled with Opal 570, red pseudocolor), (D) AE1/3
Pancytokeratin (labeled with Opal 650, magenta pseudocolor), (E) CD20 (labeled with Opal 690, cyan pseudocolor), and (F) cell phenotype map of the
same core as in Figure 1A identifying the cell populations defined by the individual markers of the multiplex immunofluorescence stain. (G) Summary
of each defined cell phenotype (pseudocolor used for visualization and associated markers). (Images shown were obtained at 10T magnification.)
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expressed: 15 were upregulated and four were down-
regulated in LN+ cases (DESeq2, adjusted p < 0.05, fold
change >1.5; Fig. 4A). Interestingly, among the most
upregulated genes in LN+ cases were extracellular matrix
(ECM) core proteins, namely, collagen type I and III (COL1A1
and COL3A1) and fibronectin 1 (FN1; Fig. 4A). We applied
IHC to study protein expression of collagen I, collagen III,
and FN1. In addition, we characterized the collagen
structure by SHG multiphoton microscopy (without the
use of antibodies). Gray level co-occurrence matrix (GLCM)
texture analysis was used to compare the SHG images. The
collagen score derived from the mean decay distance of the
SHG signal showed that the structure of collagen I was
significantly associated with LN spread: 17.72 (interquartile
range [IQR] 11.52–34) in LN+ versus 13.43 (IQR 9.14–21.46)
in LN– (p < 0.001; Fig. 4B). In contrast to the findings
regarding the collagen structure, collagen I staining
(assaying for its level) within the stroma did not showany statistically significant differences between the two
groups: 32.92 (95% confidence interval [CI] 29.89–21.8) in
LN+ versus 29.87 (95% CI 21.8–37.49) in LN– (p = 0.189;
Fig. 4C). Tumors often display a fibrotic stroma, which is
characterized by increased collagen deposition as well as
altered organization, such as increased collagen density and
collagen fiber elongation [21,22]. In the presence of
unaltered overall collagen abundance, the observed in-
creased SHG collagen I density score in LN+ patients eludes
to a stroma with increased cross-linking and elongated
collagen fibers. Collagen III staining within epithelial and
stromal compartments was significantly increased in LN+
cases: 22.28 (95% CI 15.93–23.79) versus 16.11 (95% CI
12.65–17.37, p = 0.006; Fig. 4D). FN1 staining was also
significantly increased in LN+ patients: 26.36 (95% CI 20.32–
36.94) versus 17.93 (95% CI 10.83–24.23, p = 0.001; Fig. 4E).
Despite their association with nodal status, none of these
ECM factors were found to be associated with the level of
stromal CD4 effector cell density (Supplementary Table 6).
Fig. 2 – Application of a lymphocytic T-cell multiplex immunofluorescence panel in prostate cancer primary tumors. (A) A spectrally unmixed prostate
cancer core stained with the lymphocytic T cell panel (panel 2). Enlarged subsections of the core highlighted in Figure 2A, showing each markers of
the composite image individually after spectral unmixing, together with DAPI nuclear marker (blue pseudocolor) and autofluorescence signal (black
pseudocolor): (B) CD8 (labeled with Opal 520, red pseudocolor), (C) CD4 (labeled with Opal 570, yellow pseudocolor), (D) AE1/3 Pancytokeratin (labeled
with Opal 620, magenta pseudocolor), (E) FoxP3 (labeled with Opal 690, green pseudocolor), (F) PD-1 (labeled with Opal 650, orange pseudocolor), and
(G) Cell phenotype map of the same core as in Figure 2A identifying the cell populations defined by the individual markers of the multiplex
immunofluorescence stain. (H) Summary of each defined cell phenotype (pseudocolor used for visualization and associated markers). (Images shown
were obtained at 10T magnification.)
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disease
A summary of the immune cell densities for the validation
cohort (184 informative cases; Supplementary Table 7),
stratified by nodal status, is presented in Supplementary
Table 8. Consistent with the findings from the discovery TMA,
stromal CD4 effector T-cell populations were significantly
decreased in LN+ patients (51.8 vs 100.5 cells/mm2, p < 0.001;
Supplementary Table 8). Insignificant trends of reduced tumor
(epithelial) CD8 cytotoxic Tcells and (epithelial or stromal) M1-
like macrophage infiltration were observed between patients
with and without nodal disease (Supplementary Table 8).
3.6. Stromal CD4 effector cells predicted presence of LN spread
A crucial question was whether different immune cell
infiltrates could be used as predictive biomarkers of LNinvasion. Since stromal CD4 effector T cells were
identified as the immune cell population reproducibly
associated with the status of nodal involvement, we
formally  tested whether stromal CD4 effector T-cell
infiltrates independently predict the presence of pelvic
nodal disease. We performed multivariate regression
analyses on data from the discovery cohort, including
standard of care clinicopathological  factors (namely pT
stage, Gleason score from RP, peak preoperative PSA level,
and percentage of positive cores) currently used to
predict the presence of regional LN metastasis according
to the Briganti nomogram [23]. Stromal CD4 effector T-
cell density remained an independent predictor of LN
spread (odds ratio [OR] = 0.15, p = 0.004; Table 3). Simi-
larly, based on data from the validation cohort, stromal
CD4 effector T-cell density remains a significant indepen-
dent predictor of LN metastasis (OR = 0.26, p < 0.001;
Table 3).
Table 2 – Comparisons of intraepithelial and stromal immune cell densities (cells/mm2) in patients with and without lymph node metastasis
Immune cell densities,
cells/mm2 (95% CI)
All (N = 94) Lymph node metastasis
LN– = 44 LN+ = 50 p value
Epithelium
M1-like macrophages 83 20.64 (17.07–27.45) 16.38 (11.01–21.15) 0.046
M2-like macrophages 83 18.46 (11.49–24.9) 16.2 (11.98–31.94) 0.895
B cells 83 2.81 (1.41–8.29) 1.7 (0.84–4.2) 0.205
CD4 effector T cells 66 23 (13.3–32.9) 18 (11.8–22) 0.093
CD4 regulatory T cells 66 3.25 (1–6.2) 1.5 (0–4.2) 0.159
CD4 PD-1–positive T cells 57 8.02 (0–18.7) 16.2 (5.87–21.7) 0.19
CD8 effector T cells 66 12.6 (6.5–21) 1.8(0.68–5.7) 0.001
CD8 regulatory T cell 66 3.8 (0.41–5.69) 2.2 (0.5–4.8) 0.772
CD8 PD-1–positive T cells 66 5.3 (0–9.4) 0 (0–6.82) 0.277
Stroma
M1-like macrophages 83 64.04 (39.11–89.31) 45.03 (39.7–55.3) 0.047
M2-like macrophages 83 65.32 (53.91–76.92) 73.83 (54.69–83.85) 0.7
B cells 83 8.9 (5.27–23.53) 7.05 (4.27–11.51) 0.193
CD4 effector T cells 66 91.35 (55.41–154.1) 32.5 (14.1–70.61) <0.001
CD4 regulatory T cells 66 4.65 (1.6–7.94) 4.71 (3.6–5.4) 0.971
CD4 PD-1–positive T cells 66 7.74 (0–16.2) 8.73 (1.8–13.3) 0.597
CD8 effector T cells 66 40.63 (28.1–95.46) 22.7 (11.5–31.38) 0.008
CD8 regulatory T cells 66 0.56 (0.29–1.9) 0.51 (0.31–1.7) 0.9
CD8 PD-1–positive T cells 66 8.1 (2.9–16.3) 4.66 (0.7–7.9) 0.06
CI = confidence interval; LN = lymph node.
Mann-Whitney test was used for all statistical calculations. Significant data on immune infiltrates are presented in bold.
Fig. 3 – Representative multiplex immunofluorescence images showing reduced immune cell infiltration in patients with (LN+; left) versus patients
without (LN–; right) LN metastasis. Images are spectrally unmixed for (A) panel 1: macrophage and B cell and (B) panel 2: T lymphocyte. LN = lymph
node.
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Fig. 4 – Extracellular matrix components with the primary tumors are increased and disorganized in patients with lymph node metastasis. (A)
Differentially expressed genes in patients with and without lymph node metastasis revealed upregulation of core ECM components (namely collagen I/
COL1A1, collagen III/COL3A1, and fibronectin 1/FN1) in patients with LN metastasis (fold change >1.5, adjusted p < 0.05). (B) Mean decay distance of the
second harmonic generation (SHG) signal emitted by fibrillar collagen I. Mean decay distance is represented by boxplots showing the second and third
quartiles of the data, with the whiskers indicating the maximum and minimum data points for LN– (n = 89) and LN+ (n = 113) cores. Outliers are
shown by individual data points. (C) Percentage of stroma positive for collagen I staining is presented as median with 95% CI in LN– (n = 41) and LN+
(n = 46) patients. Collagen I was restricted to stroma, and in order to avoid confounding from the relative epithelial/stromal ratio in each core, we
quantified the presence of collagen I within the stromal compartment only. (D) Percentage (%) of collagen III staining is presented as median with 95%
CI in LN– (n = 44) and LN+ (n = 47) patients. Lymph node–positive tumors had higher collagen III immunoreactivity. (E) Percentage of FN1 staining is
presented as median with 95% CI in LN– (n = 34) and LN+ (n = 45) patients. Two-tailed Mann-Whitney test was used for all statistical comparisons.
CI = confidence interval; ECM = extracellular matrix; LN = lymph node.
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Table 3 – Multivariate regression analysis of stromal CD4 effector T cells with standard of care clinicopathological factors commonly used for
the prediction of nodal metastasis
OR 95% CI p value
Discovery cohort
pT stage 2.96 0.72–12.12 0.131
Gleason score 1.05 0.24–4.57 0.944
Peak preop PSA 0.99 0.94–1.03 0.719
Percentage of positive cores 1.01 0.99–1.03 0.175
Number of lymph nodes excised 0.95 0.87–1.03 0.254
High stromal CD4 effector T cells 0.15 0.04–0.53 0.004
Validation TMA
pT stage 2.49 1.17–5.27 0.017
Gleason score 3.74 1.48–9.44 0.005
Peak preop PSA 1.04 1.02–1.5 <0.001
High stromal CD4 effector T cells 0.26 0.12–0.54 <0.001
CI = confidence interval; OR = odds ratio; PSA = prostate-specific antigen; TMA = tissue microarray.
For pT stage, the reference was pT2 versus pT3–4. For Gleason score, the reference was Gleason score 7 versus Gleason score >7.
In the discovery cohort, high density of stromal CD4 effector T cells (upper two tertiles) was an independent predictor of lymph node metastasis. In the
validation cohort, high density of stromal CD4 effector T cells (upper tertile) was an independent predictor of lymph node metastasis. Significant data on
immune infiltrates are presented in bold.
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improved survival
During tumor progression, pelvic LNs are common sites for
metastases. All cancer staging systems, including the TNM
staging system for PCa, assess the presence of LN involvement
as part of clinical evaluation of patient prognosis [24]. Apply-
ing Youden’s Index analysis, we determined the threshold
CD4 effector T-cell density in the validation cohort to be
53.15 cells/mm2, which was applied to the discovery and
validation cohorts as a cutoff to define the CD4 effector status
in a multivariate generalized linear model in predicting nodal
status: discoverycohort (n = 94), p = 0.015; validation cohort
(n = 182), p = 0.0003. An ROC analysis showed increased area
under the curve (AUC) with the addition of CD4 effector T-cell
status, although not reaching statistical significance by
Delong’s test (discovery cohort: AUC = 60.2 vs 70.6,
p = 0.13; validation cohort: AUC = 78.1 vs 80.5, p = 0.32;
Fig. 5A and B). Decision curve analysis was then performed
showing the standardized net benefit for risk thresholds,
suggesting that the addition of CD4 effector cell status may
improve the performance in detecting nodal metastasis
(solid green vs solid red line in Fig. 5C), with the greatest
benefit versus risk (signified by the largest difference
between true positive and false positive findings) in patients
with medium risk (risk threshold range of 0.4–0.6; Fig. 5D). In
addition, analysis of the overall positive and the true positive
for node-positive disease also suggested the usefulness of
CD4 effector cell status as a marker in the medium- to high-
risk range (risk threshold >0.4; Fig. 5E). Consistent with the
literature, the presence of nodal metastasis was associated
with less favorable relapse-free survival in the validation
cohort (Fig. 5F). Applying tumor stromal CD4 effector T-cell
density to stratify patients in the validation cohort, patients
with reduced CD4 effector T cells were found to have poorer
relapse-free survival outcome (Cox’s proportional hazards
model p = 0.03, hazard ratio = 1.49, n = 168, 132 events;
Fig. 5G).4. Discussion
To the best of our knowledge, this is the first study to have
carried out a comprehensive analysis of the tumor immune
infiltrates and the tumor transcriptome to investigate for
potential associations with PCa pelvic nodal metastasis.
There has been significant progress in gene expression
approaches to PCa prognostication [25]. However, there has
been little advancement in protein-based approaches, even
though dysregulated protein expression is more directly
linked with the phenotype of invasive PCa. We propose that
the addition of stromal CD4 effector T-cell immune cell
density of intermediate- and high-risk tumors can improve
the current algorithms of nodal metastasis prediction tools
such as the Briganti nomogram [23]. This could easily be
implemented at the diagnostic biopsy setting and poten-
tially spare patients from the unnecessary side effects of LN
dissection. Similarly, a tumor immune signature informed
decision on whole pelvic radiation can be based on the
likelihood of nodal disease. While the adoption of quanti-
tative mIF in the clinical setting may be challenging, future
optimization of a chromogenic IHC assay warrants assess-
ment in diagnostic prostate needle biopsy cores.
For the first time, we show that stromal CD4 effector T-
cell infiltration significantly correlates with LN metastasis
in PCa. Even though CD8 T-cell infiltration is generally
accepted as a tumor suppressive immune subpopulation,
CD4 effector T cells have been highlighted as key players of
the immune response [26]. Effector helper T cells are
essential for the initiation and maintenance of anticancer
immune responses. They are known to induce the
transformation of cytotoxic T cells into long-lived functional
effector cells [27].
Impaired immune infiltrates in progressing tumors may
result from the lack of migration cues mediated by
chemokines required for T-cell receptor stimulation. Data
from our transcriptomic analysis on chemokine expression
was not conclusive, with three chemokines found to be
Fig. 5 – Clinical impact of stromal CD4 effector T cells in lymph node metastasis and survival. ROC curves of multivariate generalized linear model
(GLM) predictions demonstrating the positive effect of adding tumor stromal CD4 effector T-cell density status to standard of care clinicopathological
factors (T stage, Gleason grade, and preoperative PSA) in predicting lymph node metastasis in the (A) discovery and (B) validation cohorts. (C–E)
Decision curve analysis for two risk models of lymph node metastasis for validation cohort (generated using R package rmda). (C) The vertical axis
showing standardized net benefit and the two horizontal axes showing the correspondence between risk threshold and cost:benefit ratio of the use of
CD effector status to predict lymph node metastasis. Baseline model (thick red line) includes standard of care clinicopathological factors (T stage,
Gleason grade, and preoperative PSA). Thick blue line signifies the addition of CD4 effector status (95% confidence intervals [CIs] by bootstrapping are
represented by thin lines of the respective colors). (D) True positive (thick black line) and false positive (dotted red line) rates as functions of the risk
threshold for the CD4 effector status risk model (95% CI thin lines). (E) Clinical impact curve for the risk model including CD4 effector status. Of 1000
patients, the black solid line shows the total number of patients deemed to be at a high risk for lymph node metastasis by low CD4 effector status for
each risk threshold. The blue dashed line shows the number of patients found to be true positive with lymph node metastasis (95% CI thin lines).
Kaplan-Meier curves of patients in the validation cohort with PCa showed shorter relapse-free survival among (F) those positive for nodal metastasis
(red = node + ve; blue = node –ve) and (G) those with a lower density of effector CD4 T cells in the stromal compartment (red = lower, blue = higher)).
Cox’s proportional hazards model was used for statistical comparisons. Stromal CD4 effector T-cell density values were dichotomized according to the
CD4 effector T-cell density threshold cutoff at 54.6 cells/mm2 (red line) or <54.6 cells/mm2 (blue line), as determined by Youden’s Index analysis.
PSA = prostate-specific antigen; ROC = receiver operator characteristic.
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AFI6 expression in tumors with nodal disease is consistent
with increased tumorigenesis, but upregulated CXCL14
levels were suggested to suppress cancer invasion. Instead,
core ECM molecules were increased at both mRNA and
protein levels in LN+ patients. Enhanced ECM deposition
and remodeling results in a more disorganized and fibrotic
stroma in LN+ patients. Tumor-associated fibrosis is a well-
established regulator of tumor progression but can also be a
critical regulator of immune surveillance [28–31]. High
collagen density may function as a physical barrier for T-cell
infiltration in pancreatic ductal adenocarcinoma and was
able to abolish completely chemokine-guided movement
[30]. Our results are consistent with the notion that a
remodeled and denser ECM may hinder effector T-cell
infiltration in PCa in the context of regional LN tumor
infiltration.
Despite the overall validity of the data produced by
multispectral imaging, some limitations should be men-
tioned. There was some degree of crosstalk between
fluorophores with overlapping emission spectra, that is,
FoxP3 Opal 690/PD-1 Opal 650 and AE1/3 Opal 620. This
problem was circumvented by phenotyping cells based on
their cellular morphology as well as marker expression.
Finally, our study suffers the key risk of undersampling due
to tumor heterogeneity. Nonetheless, the fact that our
immune signature was validated in an independent cohort
provides confidence to our working model.
While the transcriptomic analysis was performed on
prostate biopsy materials, we have carefully selected the
biopsy cores from the respective index lesions that were
incorporated in the TMA; thus data from transcriptomic
analysis are relevant to observations from the mIF experi-
ment. Furthermore, candidate genes identified to be
differentially expressed were further studied at the protein
level (including the level of stromal collagen or fibronectin
present) using the same TMA studied for mIF. In this way,
data on candidate markers within the ECM can be
interpreted with confidence to tumor immune infiltrates.
To date, no clear causality between ECM density and
immune exclusion has been established in PCa. Indeed, we
did not find a clear relationship between expression of ECM
proteins and CD4 effector status. The efficacy of single-
agent immunotherapies in PCa have so far been unsuccess-
ful [32]. Our data suggest that stratification of PCa tumors
based on tumor microenvironment warrants further
investigations. Finally, the discovery cohort was selected
to include similar number of patients with and without
nodal metastasis. As a result of such biased nature, we have
not included this cohort in patient outcome analysis. Future
evaluation of CD4 effector cell density in additional clinical
cohorts is required.
5. Conclusions
Decreased T-cell infiltrates in the primary tumor (particu-
larly CD4 effector cells) are associated with a higher risk of
LN metastasis. Future evaluation of CD4-based assays onPCa diagnostic biopsy materials may improve selection of
at-risk patients for treatment of LN metastasis.
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